利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.049 秒)

    Drug cores for sustained release of therapeutic agents
    1.
    发明授权
    Drug cores for sustained release of therapeutic agents 有权
    用于持续释放治疗剂的药物核心

    公开(公告)号：US08628792B2

    公开(公告)日：2014-01-14

    申请号：US13367823

    申请日：2012-02-07

    申请人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene De Juan, Jr. ,  Cary J. Reich

    发明人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene De Juan, Jr. ,  Cary J. Reich

    IPC分类号： A61F2/00 ,  B28B11/12

    CPC分类号： A61K9/0051 ,  A61F9/0017 ,  A61F9/00772 ,  A61F2230/0069 ,  A61F2250/0067 ,  A61K31/5575 ,  A61K47/34 ,  A61L27/54 ,  A61L2300/41 ,  A61L2300/602 ,  A61L2300/802 ,  Y02A50/395

    摘要： A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.

    摘要翻译： 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体，其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露，并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中，插入体抑制治疗剂的释放，例如具有对治疗剂基本上不可渗透的材料，使得治疗量通过暴露表面释放，从而避免将治疗剂释放到非靶组织 。

    Drug cores for sustained release of therapeutic agents
    2.
    发明申请
    Drug cores for sustained release of therapeutic agents 审中-公开
    用于持续释放治疗剂的药物核心

    公开(公告)号：US20090104243A1

    公开(公告)日：2009-04-23

    申请号：US12231986

    申请日：2008-09-05

    申请人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene de Juan, JR. ,  Cary J. Reich

    发明人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene de Juan, JR. ,  Cary J. Reich

    IPC分类号： A61K9/14 ,  A61P27/06

    CPC分类号： A61K9/0051 ,  A61F9/0017 ,  A61F9/00772 ,  A61F2230/0069 ,  A61F2250/0067 ,  A61K31/5575 ,  A61K47/34 ,  A61L27/54 ,  A61L2300/41 ,  A61L2300/602 ,  A61L2300/802 ,  Y02A50/395

    摘要： A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.

    摘要翻译： 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体，其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露，并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中，插入体抑制治疗剂的释放，例如具有对治疗剂基本上不可渗透的材料，使得治疗量通过暴露表面释放，从而避免将治疗剂释放到非靶组织 。

    DRUG CORES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS
    3.
    发明申请
    DRUG CORES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS 有权
    用于持续释放治疗药物的药物

    公开(公告)号：US20120187594A1

    公开(公告)日：2012-07-26

    申请号：US13367823

    申请日：2012-02-07

    申请人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene de Juan ,  Cary J. Reich

    发明人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene de Juan ,  Cary J. Reich

    IPC分类号： B28B11/12

    CPC分类号： A61K9/0051 ,  A61F9/0017 ,  A61F9/00772 ,  A61F2230/0069 ,  A61F2250/0067 ,  A61K31/5575 ,  A61K47/34 ,  A61L27/54 ,  A61L2300/41 ,  A61L2300/602 ,  A61L2300/802 ,  Y02A50/395

    摘要： A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.

    摘要翻译： 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体，其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露，并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中，插入体抑制治疗剂的释放，例如具有对治疗剂基本上不可渗透的材料，使得治疗量通过暴露表面释放，从而避免将治疗剂释放到非靶组织 。

    DRUG DELIVERY IMPLANTS FOR INHIBITION OF OPTICAL DEFECTS
    5.
    发明申请
    DRUG DELIVERY IMPLANTS FOR INHIBITION OF OPTICAL DEFECTS 审中-公开
    用于抑制光学缺陷的药物递送植入物

    公开(公告)号：US20100114309A1

    公开(公告)日：2010-05-06

    申请号：US12521543

    申请日：2007-12-21

    申请人： Eugene de Juan, JR. ,  Cary J. Reich ,  Stephen Boyd ,  Hanson S. Gifford ,  Mark Deem

    发明人： Eugene de Juan, JR. ,  Cary J. Reich ,  Stephen Boyd ,  Hanson S. Gifford ,  Mark Deem

    IPC分类号： A61F2/16

    CPC分类号： A61F9/0017 ,  A61F9/00772 ,  A61F9/00781 ,  A61K9/0051

    摘要： An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and/or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface.

    摘要翻译： 用于眼睛的植入物包括可植入结构和治疗剂。 治疗剂可以从结构递送到眼睛中，以便治疗影响和/或稳定眼睛的折射性质。 在许多实施例中，眼睛的屈光性可以包括近视，远视或散光中的至少一种。 治疗剂可以包含治疗影响或稳定眼睛的折射性质的组合物。 治疗剂可以包括散瞳剂或瘫痪药物中的至少一种。 例如，治疗剂可以包括睫状肌麻痹症，其包括阿托品，环戊二酸酯，琥珀酰胆碱，同质素，东莨菪碱或托品酰胺中的至少一种。 在许多实施例中，保持元件可以附接到结构以沿着天然组织表面保持结构。